Skinlite Cream

Product Introduction

Skinlite Cream is a prescription medicine designed to treat melasma. It promotes rapid skin renewal while providing relief from redness, swelling, and itching.

Use it as directed by your doctor. Wash your hands before application, and always check the label for directions. This medication is intended for external use only.

Avoid exceeding the recommended dose and inform your doctor if you have any known allergies to this medication. Common side effects include burning, irritation, itchiness, and redness at the application site.

Uses

• Treatment of Melasma

Benefits

In Treatment of Melasma

It effectively treats melasma, a common skin condition that causes dark, discolored patches, especially in women. It lightens dark patches often caused by pregnancy, birth control pills, hormone treatments, or skin injury. The cream blocks the skin’s discoloration process and reduces redness, rash, pain, and itchiness associated with melasma.

This treatment enhances your appearance, boosting your self-esteem and confidence. Always follow the prescribed dosage and duration to gain the full benefits.

Side Effects

Most side effects are mild and disappear as your body adjusts to the medication. Consult your doctor if they persist or cause concern.

Common Side Effects

• Application site reactions: burning, irritation, itching, and redness

How to Use

Use It externally as directed by your doctor. Follow the label instructions, clean and dry the affected area, and apply the cream. Wash your hands after application, unless your hands are the treated area.

How It Works

It combines three active ingredients: Hydroquinone, Mometasone, and Tretinoin, to treat melasma (dark spots on the skin). Hydroquinone lightens the skin by reducing melanin production, which causes skin darkening, though this effect is reversible.

Mometasone, a steroid, blocks the production of prostaglandins, chemicals that cause skin redness, swelling, and itching. Tretinoin, a form of vitamin A, accelerates skin renewal.